Close Menu

NEW YORK (GenomeWeb) – Leerink today downgraded Foundation Medicine's shares following Roche's announcement that it will acquire a majority stake in the cancer genomics diagnostics firm. 

Analyst Dan Leonard downgraded Foundation to Market Perform from a previous Outperform rating, while he raised the target price on the company's shares to $50 from $30. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.